Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibo Jiang

Showing results (11-20 of 580) with videos related to

Pageof 58
Sort By:
Future Microbiology|June 5, 2009
Drug-resistant viruses may repair impaired fitness by mutations outside the drug target siteLifeng Cai, Shibo Jiang
Future Virology|March 24, 2020
Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodiesLanying Du, Shibo Jiang
Advances in Experimental Medicine and Biology|April 12, 2022
Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41Fei Yu, Shibo Jiang
Lancet (London, England)|August 8, 2006
Microbicides: stopping HIV at the gateAlan Stone, Shibo Jiang
Plos Currents|March 2, 2012
E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humansChungen Pan, Shibo Jiang
Trends in Immunology|September 1, 2020
Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2Shibo Jiang, Lanying Du
Microbes and Infection|December 23, 2014
Combating the emerging viral infectious diseasesShibo Jiang, Peter J Hotez
Microbes and Infection|October 11, 2017
Combating flu in ChinaShibo Jiang, David M Ojcius
Virologica Sinica|February 16, 2020
The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome CoronavirusShibo Jiang, Zheng-Li Shi
Expert Opinion on Therapeutic Patents|November 28, 2014
Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014)Dongmei Zhang, Wen Li, Shibo Jiang
Pageof 58

Showing results (11-20 of 580) with videos related to

Sort By:
Pageof 58
Future Microbiology|June 5, 2009
Drug-resistant viruses may repair impaired fitness by mutations outside the drug target siteLifeng Cai, Shibo Jiang
Future Virology|March 24, 2020
Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodiesLanying Du, Shibo Jiang
Advances in Experimental Medicine and Biology|April 12, 2022
Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41Fei Yu, Shibo Jiang
Lancet (London, England)|August 8, 2006
Microbicides: stopping HIV at the gateAlan Stone, Shibo Jiang
Plos Currents|March 2, 2012
E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humansChungen Pan, Shibo Jiang
Trends in Immunology|September 1, 2020
Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2Shibo Jiang, Lanying Du
Microbes and Infection|December 23, 2014
Combating the emerging viral infectious diseasesShibo Jiang, Peter J Hotez
Microbes and Infection|October 11, 2017
Combating flu in ChinaShibo Jiang, David M Ojcius
Virologica Sinica|February 16, 2020
The First Disease X is Caused by a Highly Transmissible Acute Respiratory Syndrome CoronavirusShibo Jiang, Zheng-Li Shi
Expert Opinion on Therapeutic Patents|November 28, 2014
Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014)Dongmei Zhang, Wen Li, Shibo Jiang
Pageof 58